| Literature DB >> 34388287 |
Sachiko Yamamoto-Kataoka1, Yuki Kataoka1,2, Kentaro Tochitani1,3, Chisato Miyakoshi1,4, Yosuke Yamamoto1.
Abstract
BACKGROUND: To combat the coronavirus disease 2019 pandemic, many countries, including Japan, implemented policies limiting social activities and encouraging preventive behaviors. This study examines the influence of such policies on the trends of 10 infectious pediatric diseases: pharyngoconjunctival fever; group A streptococcal pharyngitis; infectious gastroenteritis; chickenpox; erythema infectiosum; hand, foot, and mouth disease; herpangina; respiratory syncytial virus; exanthem subitum; and mumps.Entities:
Keywords: communicable disease; data collection; epidemiology; public policy; universal precaution
Mesh:
Year: 2022 PMID: 34388287 PMCID: PMC8447317 DOI: 10.1111/ped.14958
Source DB: PubMed Journal: Pediatr Int ISSN: 1328-8067 Impact factor: 1.617
The annual number of reported cases for the 10 target diseases during the observation period
| Disease name/year | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|
| Pharyngoconjunctival fever | 42 853 | 43 331 | 52 535 | 44 372 | 40 949 | 21 226 |
| Group A streptococcal pharyngitis | 255 406 | 249 252 | 234 348 | 230 083 | 216 000 | 152 618 |
| Infectious gastroenteritis | 618 169 | 565 980 | 559 651 | 505 412 | 537 136 | 276 308 |
| Chickenpox | 46 651 | 38 615 | 35 480 | 31 204 | 32 953 | 20 959 |
| Erythema infectiosum | 57 786 | 42 271 | 7,979 | 14 626 | 67 227 | 17 338 |
| Hand, foot, and mouth disease | 186 164 | 17 392 | 156 878 | 59 591 | 238 006 | 9,521 |
| Herpangina | 50 949 | 66 796 | 40 098 | 39 980 | 51 128 | 6,167 |
| RSV | 31 207 | 26 770 | 30 173 | 39 712 | 40 410 | 12 274 |
| Exanthem subitum | 49 256 | 45 225 | 44 148 | 42 318 | 38 446 | 34 843 |
| Mumps | 35 798 | 88 116 | 54 576 | 15 221 | 9,644 | 4,663 |
RSV, respiratory syncytial virus.
Fig. 1Trends for 10 infectious diseases: (a) pharyngoconjunctival fever; (b) group A streptococcal pharyngitis; (c) infectious gastroenteritis; (d) chickenpox; (e) erythema infectiosum; (f) hand, foot, and mouth disease; (g) herpangina; (h) respiratory syncytial virus; (i) exanthem subitum; (j) mumps. Blue line shows the trend for 2015, orange line for 2016, gray line for 2017, yellow line for 2018, green line for 2019, and black line for 2020.
The effects of each independent variable on the number of cases per week per sentinel site in the main analysis
| Disease name | Independent variables | Crude beta‐coefficient | 95% CI | Adjusted beta‐coefficient | 95% CI | ||||
|---|---|---|---|---|---|---|---|---|---|
| Pharyngoconjunctival fever | 10–30 weeks in each year from 2015–2020 | 0.143 | 0.096 | ‐ | 0.189 | 0.216 | 0.171 | ‐ | 0.261 |
| 2020 | −0.249 | −0.305 | ‐ | −0.193 | 0.059 | 0.003 | ‐ | 0.114 | |
| anti‐COVID‐19 policies | −0.311 | −0.354 | ‐ | −0.268 | −0.440 | −0.515 | ‐ | −0.365 | |
| Group A streptococcal pharyngitis | 10–30 weeks in each year from 2015–2020 | −0.147 | −0.382 | ‐ | 0.089 | 0.183 | −0.035 | ‐ | 0.400 |
| 2020 | −0.891 | −1.294 | ‐ | −0.489 | 0.492 | −0.111 | ‐ | 1.096 | |
| anti‐COVID‐19 policies | −1.450 | −1.733 | ‐ | −1.167 | −1.977 | −2.646 | ‐ | −1.307 | |
| Infectious gastroenteritis | 10–30 weeks in each year from 2015–2020 | −0.999 | −1.495 | ‐ | −0.503 | −0.452 | −0.907 | ‐ | 0.003 |
| 2020 | −2.967 | −3.714 | ‐ | −2.220 | −0.667 | −1.772 | ‐ | 0.438 | |
| anti‐COVID‐19 policies | −4.069 | −4.408 | ‐ | −3.729 | −3.286 | −4.449 | ‐ | −2.123 | |
| Chickenpox | 10–30 weeks in each year from 2015–2020 | −0.052 | −0.100 | ‐ | −0.005 | −0.014 | −0.066 | ‐ | 0.038 |
| 2020 | −0.169 | −0.225 | ‐ | −0.114 | −0.007 | −0.090 | ‐ | 0.076 | |
| anti‐COVID‐19 policies | −0.243 | −0.284 | ‐ | −0.202 | −0.232 | −−0.324 | ‐ | −0.139 | |
| Erythema infectiosum | 10–30 weeks in each year from 2015–2020 | −0.003 | −0.094 | ‐ | 0.087 | 0.057 | −0.047 | ‐ | 0.160 |
| 2020 | −0.217 | −0.296 | ‐ | −0.137 | 0.036 | −0.091 | ‐ | 0.163 | |
| anti‐COVID‐19 policies | −0.308 | −0.366 | ‐ | −0.249 | −0.361 | −0.505 | ‐ | −0.217 | |
| Hand, foot, and mouth disease | 10–30 weeks in each year from 2015–2020 | 1.458 | 0.952 | ‐ | 1.964 | 1.761 | 1.169 | ‐ | 2.354 |
| 2020 | −1.287 | −1.720 | ‐ | −0.854 | −0.014 | −0.048 | ‐ | 0.021 | |
| Anti‐COVID‐19 policies | −1.234 | −1.644 | ‐ | −0.823 | −1.819 | −2.412 | ‐ | −1.226 | |
| Herpangina | 10–30 weeks in each year from 2015–2020 | 0.614 | 0.437 | ‐ | 0.792 | 0.725 | 0.518 | ‐ | 0.932 |
| 2020 | −0.461 | −0.619 | ‐ | −0.303 | 0.004 | −0.001 | ‐ | 0.008 | |
| Anti‐COVID‐19 policies | −0.414 | −0.568 | ‐ | −0.259 | −0.663 | −0.876 | ‐ | −0.450 | |
| RSV | 10–30 weeks in each year from 2015–2020 | −0.185 | −0.248 | −0.121 | −0.175 | −0.245 | ‐ | −0.104 | |
| 2020 | −0.226 | −0.283 | ‐ | −0.168 | −0.183 | −0.247 | ‐ | −0.119 | |
| Anti‐COVID‐19 policies | −0.293 | −0.340 | ‐ | −0.246 | −0.061 | −0.142 | ‐ | 0.021 | |
| Exanthem subitum | 10–30 weeks in each year from 2015–2020 | 0.157 | 0.130 | ‐ | 0.184 | 0.162 | 0.135 | ‐ | 0.189 |
| 2020 | −0.095 | −0.143 | ‐ | −0.047 | −0.076 | −0.123 | ‐ | −0.029 | |
| Anti‐COVID‐19 policies | −0.044 | −0.098 | ‐ | 0.011 | −0.027 | −0.099 | ‐ | 0.046 | |
| Mumps | 10–30 weeks in each year from 2015–2020 | 0.033 | −0.068 | ‐ | 0.135 | 0.040 | −0.071 | ‐ | 0.151 |
| 2020 | −0.380 | −0.432 | ‐ | −0.329 | −0.352 | −0.444 | ‐ | −0.260 | |
| Anti‐COVID‐19 policies | −0.359 | −0.410 | ‐ | −0.308 | −0.040 | −0.152 | ‐ | 0.071 | |
CI, confidential interval; RSV, respiratory syncytial virus.